In short
This article discusses a clinical trial investigating the use of Methyl Aminolevulinate Hydrochloride, a drug found in Metvix 160 mg/g Cream, for treating frontal fibrosing alopecia (FFA). The study combines microneedling and photodynamic therapy to potentially reduce inflammation and improve hair density in adult patients with FFA. This phase II trial aims to evaluate the effectiveness of this innovative approach in managing this challenging hair loss condition.
At a glance
- Drug Name
- Methyl Aminolevulinate Hydrochloride (Metvix 160 mg/g Cream)
- Condition Studied
- Frontal Fibrosing Alopecia (FFA)
- Treatment Approach
- Microneedling and Photodynamic Therapy
- Primary Objective
- Reduction of FFA inflammation at week 32 compared to baseline
- Key Eligibility Criteria
- Adults ≥18 years, classic FFA with grade 2 or 3 erythema and hyperkeratosis
- Primary Endpoint
- Reduction in combined scoring of erythema and hyperkeratosis at week 32
- Secondary Endpoints
- Changes in FFA Global Staging Score, hair density, and patient/investigator assessments
- Treatment Duration
- 32 weeks with assessments at weeks 0, 4, 8, 20, and 32
- Drug Administration
- Topical application, maximum 2 ml daily, 8 ml total
- Trial Phase
- Phase II
What is Methyl Aminolevulinate Hydrochloride?
Methyl Aminolevulinate Hydrochloride is a medication used in a treatment called photodynamic therapy (PDT). It's available as a cream called Metvix, which contains 160 mg/g of the active substance. This medication is also known by its chemical name, (4-methoxycarbonyl-2-oxo-butyl)azanium chloride.
Frontal Fibrosing Alopecia
Frontal Fibrosing Alopecia (FFA) is a medical condition that this treatment aims to address. FFA is a type of hair loss that affects the front part of the scalp, leading to a receding hairline. It's characterized by inflammation and scarring in the affected area.
Treatment Approach
The treatment approach being studied combines two methods:
- Microneedling (MN): This involves using tiny needles to create small punctures in the skin, which can stimulate healing and potentially improve the absorption of medications.
- Photodynamic Therapy (PDT): This uses Methyl Aminolevulinate Hydrochloride cream along with light exposure to target and treat the affected areas.
The treatment is applied topically (on the skin) to the affected areas of the scalp.
Eligibility Criteria
To be eligible for this treatment, patients must meet certain criteria:
- Be at least 18 years old
- Have classic FFA with moderate to severe redness and scaling (grade 2 or 3 of erythema and hyperkeratosis)
- Be able to communicate in Norwegian or English
- Be capable of giving informed consent
- If female and of reproductive age, use effective contraception
Some conditions that would prevent a person from being eligible include:
- Having certain skin conditions in the treatment area (like melanoma or other skin cancers)
- Recent use of certain medications (like systemic anti-inflammatory drugs or topical corticosteroids)
- Pregnancy or breastfeeding
- High blood pressure (160/100 mm Hg or higher)
These criteria ensure that the treatment is safe and appropriate for the participants.
Treatment Goals
The main goal of this treatment is to reduce inflammation caused by FFA. Specifically, the study aims to:
- Reduce redness and scaling in the affected area
- Improve the overall appearance of FFA
- Slow down or stop the progression of hair loss
- Potentially increase hair density in some cases
These goals will be measured at various time points throughout the study, with the main assessment occurring at 32 weeks after starting treatment.
Potential Benefits
While the effectiveness of this treatment is still being studied, potential benefits may include:
- Reduction in scalp inflammation
- Improvement in the appearance of the hairline
- Slowing or stopping of further hair loss
- Possible regrowth of hair in some cases
It's important to note that individual results may vary, and the full extent of benefits will be determined through the ongoing clinical trial.